Vivos Therapeutics Inc (VVOS) reports strong revenue growth and strategic advancements, despite facing increased net losses and market uncertainties.
Vivos Therapeutics, Inc. ( NASDAQ: VVOS) Q3 2024 Earnings Conference Call November 14, 2024 5:00 PM ET Kirk Huntsman - Chariman & CEO Brad Amman - CFO Scott Henry - Alliance Global Partners Lucas Ward ...
Revenue Increased 17% Quarter over QuarterOperating Loss Decreased 27% Management to Host Conference Call Today at 5:00 pm ETLITTLETON, Colo., ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback